Tolero Pharmaceuticals, Inc.

Mannkind Corporation

University of Utah Research Foundation

Sumitomo Dainippon Pharma Oncology, Inc.

Sumitomo Pharma Oncology, Inc.

Alexis Mollard

Steven L Warner

Gary A Flynn

Hariprasad Vankayalapati

David J Bearss

Mary Faris

Qingping Zeng

Sunil Sharma

Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, R, R, R, R, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

JAK1 and ALK2 inhibitors and methods for their use

JAK2 and ALK2 inhibitors and methods for their use

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

Multiple kinase pathway inhibitors

In one aspect, the invention relates to substituted N-phenylpyrimidin-2-amine analogs, derivatives thereof, and related compounds, which are useful as inhibitors of Axl kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of the Axl kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase

Growing community of inventors

Salt Lake City, UT, United States of America

Alexis Mollard